Cetuximab and panitumumab are monoclonal antibodies against the epidermal growth factor receptor (EGFR) that have been demonstrated to improve outcomes in mCRC patients with wild-type (WT) status compared to the anti-VEGF used as the first line of treatment [9,10,11], particularly in those patients whose primary tumour originated in the left side of the colon [12,13,14,15,16,17]. This evidence concerns the gene VEGFA and neoplasm.